Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry disease

Polyethylene glycol (PEG)ylated drugs are used for medical treatment, since PEGylation either decreases drug clearance or/and shields the protein from undesirable immunogenicity. PEGylation was implemented in a new enzyme replacement therapy for Fabry disease (FD), pegunigalsidase-alfa (PRX-102). Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenders, Malte, Feidicker, Lina Marleen, Brand, Stefan-Martin, Brand, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561604/
https://www.ncbi.nlm.nih.gov/pubmed/37818380
http://dx.doi.org/10.3389/fimmu.2023.1266082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561604/
https://www.ncbi.nlm.nih.gov/pubmed/37818380
http://dx.doi.org/10.3389/fimmu.2023.1266082

Ejemplares similares